Posted by Michael Wonder on 19 Jul 2017
Institute for Clinical and Economic Review to evaluate CAR-T therapies in upcoming report
19 July 2017 - Report tentatively expected to review axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis).
The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness and value of chimeric antigen receptor T-cell (CAR-T) therapies for treatment of certain types of cancer.
The report is tentatively expected to consider two therapies currently under review by the FDA: axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis).
